Rapid symptomatic improvement in two patients with ganglioglioma after restarting BRAF inhibitor therapy

Pediatric Blood & CancerVolume 70, Issue 7 e30296 LETTER TO THE EDITOR Rapid symptomatic improvement in two patients with ganglioglioma after restarting BRAF inhibitor therapy Evan Cantor, Corresponding Author Evan Cantor [email protected] orcid.org/0000-0001-7302-9734 Division of Hematology and Oncology, Connecticut Children's Medical Center, Hartford, Connecticut, USA Department of Pediatrics, UCONN School of Medicine, Farmington, Connecticut, USA Correspondence Evan Cantor, Division of Hematology and Oncology, Connecticut Children's Medical Center, 5a, 282 Washington St, Hartford, CT 06106, USA. Email: [email protected]Search for more papers by this authorRachel Berkovich, Rachel Berkovich Departments of Radiology, Children's Mercy Hospital, Kansas City, Missouri, USASearch for more papers by this authorPournima Navalkele, Pournima Navalkele Division of Pediatric Oncology, Children's Hospital of Orange County, Orange, California, USASearch for more papers by this authorNicole M. Brossier, Nicole M. Brossier Departments of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USASearch for more papers by this author Evan Cantor, Corresponding Author Evan Cantor [email protected] orcid.org/0000-0001-7302-9734 Division of Hematology and Oncology, Connecticut Children's Medical Center, Hartford, Connecticut, USA Department of Pediatrics, UCONN School of Medicine, Farmington, Connecticut, USA Correspondence Evan Cantor, Division of Hematology and Oncology, Connecticut Children's Medical Center, 5a, 282 Washington St, Hartford, CT 06106, USA. Email: [email protected]Search for more papers by this authorRachel Berkovich, Rachel Berkovich Departments of Radiology, Children's Mercy Hospital, Kansas City, Missouri, USASearch for more papers by this authorPournima Navalkele, Pournima Navalkele Division of Pediatric Oncology, Children's Hospital of Orange County, Orange, California, USASearch for more papers by this authorNicole M. Brossier, Nicole M. Brossier Departments of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USASearch for more papers by this author First published: 14 March 2023 https://doi.org/10.1002/pbc.30296 An abstract describing case 1 was previously published at ISPNO, June, 2022 under the title “Rapid symptomatic improvement for a patient treated with BRAF inhibition for BRAFV600E mutated ganglioglioma” (DOI: 10.1093/neuonc/noac079.720). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1Nobre L, Zapotocky M, Ramaswamy V, et al. Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis Oncol. 2020; 4: 561- 571. 2Nicolaides T, Nazemi KJ, Crawford J, et al. Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget. 2020; 11(21): 1942- 1952. 3Manoharan N, Choi J, Chordas C, et al. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. J Neurooncol. 2020; 149(2): 253- 262. 4Philippe L, Maria K, Tariq A, et al. Efficacy of Dabrafenib for three children with brainstem BRAF(V600E) positive ganglioglioma. J Neurooncol. 2019; 145(1): 135- 141. 5Pekmezci M, Villanueva-Meyer JE, Goode B, et al. The genetic landscape of ganglioglioma. Acta Neuropathol Commun. 2018; 6(1): 47. 6Koh HY, Kim SH, Jang J, et al. BRAF somatic mutation contributes to intrinsic epileptogenicity in pediatric brain tumors. Nat Med. 2018; 24(11): 1662- 1668. 7Goz RU, Akgül G, LoTurco JJ. BRAFV600E expression in neural progenitors results in a hyperexcitable phenotype in neocortical pyramidal neurons. J Neurophysiol. 2020; 123(6): 2449- 2464. 8Cantor E, Meyer A, Morris SM, et al. Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1. Childs Nerv Syst. 2022; 38(11): 2245- 2249. Volume70, Issue7July 2023e30296 ReferencesRelatedInformation